logo

Cabaletta Bio, Inc. (CABA)



Trade CABA now with
  Date
  Headline
5/6/2020 8:04:47 AM Cabaletta Bio Gets FDA Fast Track Designation For DSG3-CAART For Treatment Of Mucosal Pemphigus Vulgaris
1/29/2020 8:11:56 AM Cabaletta Bio: FDA Grants DSG3-CAART Orphan Drug Designation For Pemphigus Vulgaris